Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.
about
Lacosamide for neuropathic pain and fibromyalgia in adultsRecommendations for the pharmacological management of neuropathic pain: an overview and literature updateEvidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and RehabilitatiLacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safetyLacosamide: what can be expected from the next new antiepileptic drug?Translational investigation and treatment of neuropathic painThe adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trialsLacosamide: a new approach to target voltage-gated sodium currents in epileptic disordersHandling missing data in a duloxetine population pharmacokinetic/pharmacodynamic model - imputation methods and selection models.Painful diabetic neuropathy: advantage of novel drugs over old drugs?Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & RehabilitationHigh-performance liquid chromatographic analysis of lacosamide in canine serum using ultraviolet detection: application to pre-clinical pharmacokinetics in dogs.EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.Duloxetine for the treatment of fibromyalgia.Update on the management of diabetic polyneuropathies.Alcoholic neuropathy: possible mechanisms and future treatment possibilitiesNovel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathyEfficacy, safety, and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutation-related small fiber neuropathy: study protocol of a randomized controlled trial-the LENSS study.Diabetic painful and insensate neuropathy: pathogenesis and potential treatments.Sodium channel blockers for the treatment of neuropathic pain.Drug interactions involving the new second- and third-generation antiepileptic drugs.Lacosamide for pain.Emerging drugs for diabetic neuropathy.Pharmacotherapy of epilepsy: newly approved and developmental agents.Pharmacological treatment of diabetic neuropathic pain.Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes.Lacosamide in patients with pharmacoresistant epilepsy.Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy.Diabetic neuropathy and oxidative stress: therapeutic perspectives.Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.An investigation of factors contributing to higher levels of placebo response in clinical trials in neuropathic pain: a systematic review and meta-analysis.Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives.Emerging drugs for diabetic peripheral neuropathy and neuropathic pain.Fibromyalgia syndrome: novel therapeutic targets.Population pharmacokinetic/pharmacodynamic models for duloxetine in the treatment of diabetic peripheral neuropathic pain.Recent advances in pharmacological treatment of neuropathic painEfficacy and safety of lacosamide in painful diabetic neuropathy.Sinus node dysfunction: an adverse effect of lacosamide.Analgesic ineffectiveness of lacosamide after spinal nerve ligation and its sodium channel activity in injured neurons.Likert pain score modeling: a Markov integer model and an autoregressive continuous model.
P2860
Q24203727-8F916C8E-2ABA-4EFD-BD48-E49685A15B89Q24616897-E2B954BD-466B-4B81-8443-5FE62241C243Q24632313-982EE845-DB49-40B2-B5B8-BF1CD06ECEB1Q24644936-19FD8771-C2F5-44EC-B5A7-D32733A9BB82Q24655596-8BBCC98D-C76C-4ABD-899E-DA0575B1B2FBQ27011346-3EA43629-38AA-44C0-8918-8E028041C36BQ27026195-7D9B1C91-547E-4E7A-9E0F-FD60F8BAB2CFQ28833549-5EA7C8AC-E40D-450A-B992-AC9ACB966047Q30813682-EED61F4A-DF9C-47A1-A72A-2DCDC88F379CQ33610824-E398D887-7AF9-4354-B1D5-8623125E4156Q33870062-900A95AD-329C-409B-BC9E-8E0E291B07A5Q34013089-D500C7A0-C301-46C6-9856-228114917BF4Q34110857-E5328F35-0352-4024-AC1D-FD6B6D5F6750Q34663934-BC8F0F88-7432-427E-89AE-7E78D5777892Q35178801-F1767B1B-0CAA-46C8-8F36-A16441C1077BQ36017359-5C56AA41-CF77-4F89-B04C-8CC8EDBCCDC5Q36329924-403F436D-AF0C-4E84-9052-48D05CC4F204Q37057835-A821E1F0-6EC2-48C1-B757-6C83122087D6Q37605348-4C5C4126-F696-4F4F-84E1-1C1B5519095EQ37605350-E301D330-B239-4DB0-84B4-655E102818FAQ37658910-42A20966-5669-4AD6-B48C-F57274A2335DQ37778066-1936EBC0-6D85-442E-90D9-A363511CE16FQ37783301-EEC2050C-294F-4456-81DD-647847F94D3CQ37831297-B65EF6EB-831E-4BB6-B793-A4C9905F0728Q37858519-43D66163-E1F9-4B7F-997D-182259DC2D1BQ37946885-5B2999F9-7C21-4881-8F2E-ACD145B208ABQ38032922-638BD046-010A-4759-AEFC-31554095608DQ38093664-75522F06-F601-453C-9AEF-7C3BAB04EC19Q38112117-22B24301-BE01-444B-B1D5-46F6CF5E2A41Q38244605-027C187A-B72E-4402-A4E5-05C94D654ACBQ38307489-33FF00F9-FF39-45F7-819D-3B468CF2EF1EQ38522262-267268E0-8F1B-46E4-B542-50A4DB6EF0FAQ38798588-9E71F804-139E-47BD-8F00-F4D7B0284B84Q38863908-EA182B66-C97C-4558-9467-7D2C2503EF38Q39243503-76EEE1B9-3E4A-4919-A203-40476DEE4DAAQ39274866-691FE49F-72C4-4CDD-97AB-6BDF5999280EQ39784392-27452798-03D2-459C-8465-20F1D50DB5B6Q44411833-DC3CB7F4-E8D3-4909-869B-CD8BED78E451Q45363773-FCE8EB4D-5D95-4261-90F3-BDC8B09EB1A8Q47999794-6B36B826-5EC1-4F3E-98E3-539962712DD2
P2860
Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Efficacy and safety of lacosam ...... trial of fixed-dose regimens.
@en
Efficacy and safety of lacosam ...... trial of fixed-dose regimens.
@nl
type
label
Efficacy and safety of lacosam ...... trial of fixed-dose regimens.
@en
Efficacy and safety of lacosam ...... trial of fixed-dose regimens.
@nl
prefLabel
Efficacy and safety of lacosam ...... trial of fixed-dose regimens.
@en
Efficacy and safety of lacosam ...... trial of fixed-dose regimens.
@nl
P2093
P1476
Efficacy and safety of lacosam ...... trial of fixed-dose regimens.
@en
P2093
James P Wymer
Jeffrey Simpson
Lacosamide SP742 Study Group
Sabine Bongardt
P304
P356
10.1097/AJP.0B013E318196D2B6
P407
P577
2009-06-01T00:00:00Z